论文部分内容阅读
目的:研究复方玄驹胶囊对类风湿关节炎患者外周血Th17细胞的比例及白介素17(IL-17)水平的影响。方法:选择类风湿关节炎患者30例和健康对照30例,类风湿关节炎患者接受复方玄驹胶囊治疗2个月。采用流式细胞仪检测外周血CD4+T淋巴细胞中Th17细胞的比例,ELISA法检测外周血中IL-17的表达水平。结果:治疗前,类风湿关节炎患者Th17细胞亚群的比例为(1.84±0.79)%,显著高于健康对照组(0.62±0.31)%。类风湿关节炎患者血清IL-17水平为387.46±82.21pg/ml,显著高于健康对照组45.36±19.31 pg/ml。复方玄驹治疗1月和2月后,类风湿关节炎患者外周血CD4+细胞中Th17细胞亚群的比例分别为为(1.93±0.58)%和(1.53±0.72)%,与治疗前相比无统计学差异。血清IL-17水平分别为为288.21±49.06pg/ml和122.47±51.26pg/ml,差异有统计学意义。复方玄驹治疗2月后,类风湿关节炎患者临床症状及炎症指标较治疗前改善,差异有统计学意义。结论:Th17细胞及其分泌的IL-17可能在类风湿关节炎的发病中起作用。复方玄驹胶囊能抑制Th17细胞分泌IL-17,但不能降低Th17细胞的比例。
Objective: To study the effect of Xuanju capsule on the proportion of Th17 cells in peripheral blood and the level of interleukin-17 (IL-17) in rheumatoid arthritis patients. Methods: 30 patients with rheumatoid arthritis and 30 healthy controls were selected. Patients with rheumatoid arthritis received compound Xuanju Capsule for 2 months. Flow cytometry was used to detect the proportion of Th17 cells in peripheral blood CD4 + T lymphocytes. The level of IL-17 in peripheral blood was measured by ELISA. Results: Before treatment, the proportion of Th17 cell subsets in patients with rheumatoid arthritis was (1.84 ± 0.79)%, significantly higher than that in healthy controls (0.62 ± 0.31)%. The level of IL-17 in patients with rheumatoid arthritis was 387.46 ± 82.21pg / ml, which was significantly higher than that in healthy controls (45.36 ± 19.31pg / ml). The rates of Th17 cell subsets in CD4 + cells from patients with rheumatoid arthritis were (1.93 ± 0.58)% and (1.53 ± 0.72)%, respectively, compared with those before treatment Statistical differences. Serum IL-17 levels were 288.21 ± 49.06pg / ml and 122.47 ± 51.26pg / ml, the difference was statistically significant. After the treatment of compound Xuanju 2 months later, the clinical symptoms and inflammatory indexes of patients with rheumatoid arthritis improved compared with those before treatment, the difference was statistically significant. Conclusion: Th17 cells and their secreted IL-17 may play a role in the pathogenesis of rheumatoid arthritis. Compound Xuanju Capsules can inhibit Th17 cells secrete IL-17, but can not reduce the proportion of Th17 cells.